If you have cash on the sidelines, now’s the time to do some buying, Jim Cramer told his Mad Money viewers Monday. That’s because the selloff didn’t begin today, Cramer said. It’s been happening for weeks.
Investors may still be digesting worries and things that have put the market into disarray, but most of those worries aren’t new. And with many stocks now well off their highs, the time to start buying is now.
Cramer listed a number of reasons why investors are selling. Many have lost hope for additional government stimulus, which means many small businesses likely won’t survive our social distancing requirements required until a vaccine is available. Travel and leisure is on the ropes as well, and we still have a lot of unpaid rents that must be reconciled.
Then there’s uncertainty about our government, including a contentious election, a Supreme Court nomination and President Donald Trump’s obsession with TikTok.
Despite all of these worries, Cramer told viewers that he thinks we’re nearing the bottom. He reminded viewers that stocks get cheaper as they go lower and selloffs like today are the sign of a healthy market.
Cramer and the AAP team are looking at everything from earnings and tariffs to the Federal Reserve. Find out what they’re telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts Plus.
Don’t miss Cramer’s best, every day, with fast, actionable strategies: StreetLightning.
Executive Decision: Ely Lilly
In his first “Executive Decision” segment of the week, Cramer spoke with David Ricks, chairman and CEO of Ely Lilly (LLY) – Get Report, the drugmaker whose shares fell 1.9% Monday, along with the broader markets, despite posting positive clinical trial data on the company’s breast cancer therapy.
Ricks explained that their treatment, when added to the current standard of care, has shown to reduce the rate of breast cancer recurrence by 25%. He called the data “great news” for patients and their families, and called it the first significant advancement in almost 20 years.
Oncology continues to be a focus for Lilly, Ricks said, which is why they recently added Loxo Oncology to their portfolio for $8 billion.
Ricks also commented on their recent work creating neutralizing antibodies to treat COVID-19 patients. He said in just six months time, they’ve gone from nothing to clinical trial data showing they can reduce hospitalization rates by as much as 72%. He said they continue to test their antibodies at hard-hit nursing homes and have partnered with Amgen (AMGN) – Get Report to help with manufacturing.
Executive Decision: Coca-Cola
Quincey said consumer tastes were changing even before COVID-19 struck, but now people are looking for new things and are blurring the lines among beverage categories. Drinks like hard seltzers have grown over 200% in the U.S. over the past year, and Coca-Cola will be joining the trend with spiked Topo-Chico, a popular sparkling mineral water, in the near future.
Coca-Cola is also working hard to support their bottlers, retailers and restaurants, all of whom have been affected by the pandemic. Quincey said Coke is upgrading their platform and evolving into a digital organization, which allows them to be faster, more agile and support all of their partners better. He said they are listening to customers and there will be innovations and announcement in the near future.
On Real Money, Cramer keys in on the companies and CEOs he knows best. Get more of his insights with a free trial subscription to Real Money.
Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.
To watch replays of Cramer’s video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer’s free Booyah! newsletter with all of his latest articles and videos please click here.
At the time of publication, Cramer’s Action Alerts PLUS had no position in the stocks mentioned.